×
About 3,378 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  987 results

Gordon syndrome caused by a CUL3 mutation in a patient with short stature in Korea: a c...
https://doi.org/10.1515/jpem-2021-0361
Journal of Pediatric Endocrinology & Metabolism : JPEM; Park JH, Kim JH et. al.

Sep 5th, 2021 - Objectives: Gordon syndrome (GS), also known as pseudohypoaldosteronism type II, is a rare tubular disease characterized by hypertension, hyperkalemia, and metabolic acidosis. Its causative genes are CUL3, KLHL3, WNK1, and WNK4, and they are assoc...

Neonatal rebound hyperkalemia associated with ritodrine alone: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405715
BMC Pediatrics; Osumi K, Suga K et. al.

Sep 2nd, 2021 - Betamimetics have been used for tocolysis extensively in the past, and one of them, ritodrine is widely used in Japan. Various adverse events have been reported for this agent, including newborn hypoglycemia and hypokalemia, as well as maternal hy...

Population Epidemiology of Hyperkalemia: Cardiac and Kidney Long-term Health Outcomes.
https://doi.org/10.1053/j.ajkd.2021.07.008
American Journal of Kidney Diseases : the Official Journa... Mclean A, Nath M et. al.

Aug 23rd, 2021 - The population burden and long-term implications of hyperkalemia have not been comprehensively studied. We studied how often and where hyperkalemia occurs as well as its independent association with survival and long-term cardiac and kidney health...

Non-steroidal anti-inflammatory drugs and risk of acute adverse renal outcomes in diabe...
https://doi.org/10.3233/JRS-200096
The International Journal of Risk & Safety in Medicine; Lim CC, Kadir HBA et. al.

Aug 17th, 2021 - Individuals with diabetes mellitus (DM) may be susceptible to non-steroidal anti-inflammatory drug (NSAID) - induced acute kidney injury (AKI) but data on NSAID-related adverse renal events is sparse. We aimed to evaluate the risk of acute kidney ...

see more →

Guidelines  1 results

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood...
https://doi.org/10.1016/j.cjca.2016.02.066
The Canadian Journal of Cardiology; Leung AA, Nerenberg K et. al.

Apr 28th, 2016 - Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 ne...

see more →

Drugs  135 results see all →

News  228 results

Fast Five Quiz: Hyperkalemia Management
https://reference.medscape.com/viewarticle/948621

Apr 9th, 2021 - Hyperkalemia is a clinically important acute electrolyte abnormality that can result in significant morbidity and life-threatening cardiac arrhythmias. Although uncommon in the general population, hyperkalemia is much more prevalent in patients wi...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.medscape.com/viewarticle/940012

Oct 29th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.staging.medscape.com/viewarticle/940012

Oct 29th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Study Supports Citrate Over Heparin Anticoagulation for Continuous Dialysis
https://www.medscape.com/viewarticle/939781

Oct 27th, 2020 - NEW YORK (Reuters Health) - A large randomized controlled trial supports the use of regional citrate over heparin anticoagulation to help prevent blood clot formation at the filter in patients receiving continuous dialysis therapies. Dialysis filt...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.medscape.com/viewarticle/939724

Oct 23rd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

see more →